IBDEI0YK ; ; 01-FEB-2022
 ;;3.0;IB ENCOUNTER FORM IMP/EXP;;FEB 01, 2022
 Q:'DIFQR(358.3)  F I=1:2 S X=$T(Q+I) Q:X=""  S Y=$E($T(Q+I+1),4,999),X=$E(X,4,999) S:$A(Y)=126 I=I+1,Y=$E(Y,2,999)_$E($T(Q+I+1),5,999) S:$A(Y)=61 Y=$E(Y,2,999) X NO E  S @X=Y
Q Q
 ;;^UTILITY(U,$J,358.3,15608,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,15608,1,3,0)
 ;;=3^Impaired Fasting Glucose
 ;;^UTILITY(U,$J,358.3,15608,1,4,0)
 ;;=4^R73.01
 ;;^UTILITY(U,$J,358.3,15608,2)
 ;;=^5019561
 ;;^UTILITY(U,$J,358.3,15609,0)
 ;;=R74.8^^61^760^1
 ;;^UTILITY(U,$J,358.3,15609,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,15609,1,3,0)
 ;;=3^Abnormal Levels of Serum Enzymes
 ;;^UTILITY(U,$J,358.3,15609,1,4,0)
 ;;=4^R74.8
 ;;^UTILITY(U,$J,358.3,15609,2)
 ;;=^5019566
 ;;^UTILITY(U,$J,358.3,15610,0)
 ;;=R03.0^^61^760^27
 ;;^UTILITY(U,$J,358.3,15610,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,15610,1,3,0)
 ;;=3^Elevated BP Reading w/o Diagnosis of HTN
 ;;^UTILITY(U,$J,358.3,15610,1,4,0)
 ;;=4^R03.0
 ;;^UTILITY(U,$J,358.3,15610,2)
 ;;=^5019171
 ;;^UTILITY(U,$J,358.3,15611,0)
 ;;=Z91.19^^61^760^53
 ;;^UTILITY(U,$J,358.3,15611,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,15611,1,3,0)
 ;;=3^Noncompliance w/ Medical Treatment/Regimen
 ;;^UTILITY(U,$J,358.3,15611,1,4,0)
 ;;=4^Z91.19
 ;;^UTILITY(U,$J,358.3,15611,2)
 ;;=^5063618
 ;;^UTILITY(U,$J,358.3,15612,0)
 ;;=E66.01^^61^760^54
 ;;^UTILITY(U,$J,358.3,15612,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,15612,1,3,0)
 ;;=3^Obesity,Morbid
 ;;^UTILITY(U,$J,358.3,15612,1,4,0)
 ;;=4^E66.01
 ;;^UTILITY(U,$J,358.3,15612,2)
 ;;=^5002826
 ;;^UTILITY(U,$J,358.3,15613,0)
 ;;=F43.11^^61^760^61
 ;;^UTILITY(U,$J,358.3,15613,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,15613,1,3,0)
 ;;=3^PTSD,Acute
 ;;^UTILITY(U,$J,358.3,15613,1,4,0)
 ;;=4^F43.11
 ;;^UTILITY(U,$J,358.3,15613,2)
 ;;=^5003571
 ;;^UTILITY(U,$J,358.3,15614,0)
 ;;=F43.12^^61^760^62
 ;;^UTILITY(U,$J,358.3,15614,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,15614,1,3,0)
 ;;=3^PTSD,Chronic
 ;;^UTILITY(U,$J,358.3,15614,1,4,0)
 ;;=4^F43.12
 ;;^UTILITY(U,$J,358.3,15614,2)
 ;;=^5003572
 ;;^UTILITY(U,$J,358.3,15615,0)
 ;;=I25.119^^61^760^5
 ;;^UTILITY(U,$J,358.3,15615,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,15615,1,3,0)
 ;;=3^Athscl Hrt Dis of Native Cor Art w/ Ang Pctrs,Unspec
 ;;^UTILITY(U,$J,358.3,15615,1,4,0)
 ;;=4^I25.119
 ;;^UTILITY(U,$J,358.3,15615,2)
 ;;=^5007111
 ;;^UTILITY(U,$J,358.3,15616,0)
 ;;=I25.10^^61^760^6
 ;;^UTILITY(U,$J,358.3,15616,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,15616,1,3,0)
 ;;=3^Athscl Hrt Dis of Native Cor Art w/o Ang Pctrs
 ;;^UTILITY(U,$J,358.3,15616,1,4,0)
 ;;=4^I25.10
 ;;^UTILITY(U,$J,358.3,15616,2)
 ;;=^5007107
 ;;^UTILITY(U,$J,358.3,15617,0)
 ;;=F17.219^^61^760^51
 ;;^UTILITY(U,$J,358.3,15617,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,15617,1,3,0)
 ;;=3^Nicotine Dependence,Cigarettes
 ;;^UTILITY(U,$J,358.3,15617,1,4,0)
 ;;=4^F17.219
 ;;^UTILITY(U,$J,358.3,15617,2)
 ;;=^5003369
 ;;^UTILITY(U,$J,358.3,15618,0)
 ;;=Z51.5^^61^760^64
 ;;^UTILITY(U,$J,358.3,15618,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,15618,1,3,0)
 ;;=3^Palliative Care Encounter
 ;;^UTILITY(U,$J,358.3,15618,1,4,0)
 ;;=4^Z51.5
 ;;^UTILITY(U,$J,358.3,15618,2)
 ;;=^5063063
 ;;^UTILITY(U,$J,358.3,15619,0)
 ;;=Z23.^^61^760^28
 ;;^UTILITY(U,$J,358.3,15619,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,15619,1,3,0)
 ;;=3^Encounter for Immunization(s)
 ;;^UTILITY(U,$J,358.3,15619,1,4,0)
 ;;=4^Z23.
 ;;^UTILITY(U,$J,358.3,15619,2)
 ;;=^5062795
 ;;^UTILITY(U,$J,358.3,15620,0)
 ;;=E11.65^^61^760^20
 ;;^UTILITY(U,$J,358.3,15620,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,15620,1,3,0)
 ;;=3^DM Type 2 Uncontrolled w/ Hyperglycemia
